MedTrace Logo

Study of Markers of Iron Metabolism and Their Relationship With Phosphocalcic and Hepatic Metabolism and Inflammation in Hemodialysis Patients

NCT05586867 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2022-10-19

No results posted yet for this study

Summary

From a scientific point of view and for publication purposes, it therefore seems important to study the metabolism of iron and in particular to define its conditions of absorption, metabolism, elimination and storage in the body at course of advanced renal failure.

The study will follow the evolution of hormones regulating iron metabolism and put into perspective their links with phosphocalcic and hepatic metabolisms as well as inflammation in hemodialysis patients.

The main objective of this program is to study the evolution of hepcidin and erythroferrone levels in hemodialysis patients. These two biomarkers regulating iron metabolism are not performed routinely in dialysis centers and are not listed in the nomenclature.

Conditions

  • Iron Metabolism Disorders
  • Calcium Phosphate Metabolism
  • Hepatic Metabolic Disorders
  • Hemodialysis Complication

Interventions

PROCEDURE

Blood test

15 mL of blood to follow the evolution of hepcidin and erythroferrone levels

Sponsors & Collaborators

  • European Clinical Trial Experts Network

    collaborator OTHER

  • Ramsay Générale de Santé

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2026-12-01
Completion
2031-12-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05586867 on ClinicalTrials.gov